Why tirzepatide ordering is a per-step economics problem on VSDH
Tirzepatide programs run across a wide titration range, and landed cost per vial can change as the patient escalates. That makes ordering economic, not just operational: to price a protocol you need per-vial 503A cost at each step, not one average buried in a partner agreement. VSDH markets GLP-1 therapies through a branded pharmacy spanning 503A and 503B suppliers; concentrations, vial sizes, and rates depend on your partner assignment, so confirm per-step economics in a live demo.
This page covers ordering workflow and economics, not clinical dosing. The titration schedule is a prescriber decision; the platform's job is to make the right vial reach the patient and show what each step costs. Evaluate whether VSDH's white-label stack or ConnectRxCare partner flows give you that visibility — or whether clinic-first pass-through pricing fits better.